- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00753324
Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia
Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia (Impact of HAART to Prevent Pediatric AIDS in Rural Zambia).
The investigators will enroll a cohort of HIV-infected pregnant women accessing PMTCT services, to better understand the incremental benefits (e.g. reduction in HIV transmission, improvements in HIV-free survival) and risks (e.g. drug toxicities) of the routine HAART strategy, in comparison to HIV-infected pregnant women accessing the Zambian Standard of Care services.
The investigators will test the hypothesis that routine use of HAART produces significant reductions in HIV transmission rates, with only minimal side effects.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Lusaka, Zambia, 34681
- CIDRZ
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV infected
- Pregnant women
- Ability to provide informed consent.
- Meets eligibility criteria for HAART initiation
Exclusion Criteria:
- Unwillingness to provide informed consent
- Below the age of legal consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Routine three-drug antiretroviral prophyalxis
Cohort of 160 HIV-infected women, approached at > 28 weeks gestation and initiated on routine HAART for the purposes of PMTCT.
|
Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV).
The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir.
In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T).
In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
|
No Intervention: Control arm
A cohort of 160 women will be enrolled from the control clinics, from 28 weeks gestation onward.
At these sites, the antenatal zidovudine will be offered, with provision of single-dose nevirapine for self-administration in labor.
This practice is in accordance with the current standard of care recommended by the Zambian National Guidelines for PMTCT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HIV Infection
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HIV Infection
Time Frame: 6 weeks, 6 months and 24 months
|
6 weeks, 6 months and 24 months
|
Infant survival
Time Frame: 12 and 24 months
|
12 and 24 months
|
HIV-free survival
Time Frame: 12 months and 24 months
|
12 months and 24 months
|
Incidence of maternal toxicity to HAART regimens
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Benjamin Chi, M.D, Centre for Infectious Disease Research in Zambia
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Anti-Infective Agents
- Antiviral Agents
- Anti-Retroviral Agents
Other Study ID Numbers
- CIDRZ 1222/F070821006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Routine three-drug antiretroviral prophylaxis
-
China-Japan Friendship HospitalRecruitingVenous Thromboembolism | Pulmonary Embolism | Deep Venous Thrombosis | Quality Improvement | Venous Thromboembolic DiseaseChina
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | Fracture
-
China-Japan Friendship HospitalNot yet recruitingPulmonary Embolism | Deep Venous Thrombosis | Venous Thromboembolic Disease
-
French National Agency for Research on AIDS and...Merck Sharp & Dohme LLC; Gilead SciencesCompletedHIV Infections | TuberculosisCôte D'Ivoire
-
PETHEMA FoundationCompleted
-
Institut de Recherche pour le DeveloppementEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV InfectionsThailand
-
Gulhane School of MedicineCompletedIdiopathic Hypogonadotropic HypogonadismTurkey
-
Pacific Coast Family Medical GroupEnrolling by invitationCancer | Atherosclerosis | Atrial Fibrillation | Insulin Resistance | Dementia | PreDiabetes | Type2 Diabetes | NASH - Nonalcoholic Steatohepatitis | Diastolic Dysfunction | Carotid Plaque
-
Guiyang Medical UniversityUnknownLocally Advanced Head and Neck Squamous Cell CarcinomaChina
-
Sinovac Research and Development Co., Ltd.Completed